Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Abstract:

:Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criteria for diagnosing MDS and discusses common diagnostic challenges. MDS needs to be separated from numerous neoplastic and non-clonal hematologic disorders that can mimic MDS, including other myeloid neoplasms, nutritional deficiencies, toxin exposures, aplastic anemia, and inherited disorders (e.g., congenital sideroblastic anemia). Some distinctions are more critical therapeutically than others; e.g., recognizing B12 deficiency is more important than parsing high-risk MDS from erythroleukemia. Diagnostically ambiguous cases may be assigned holding-pattern terms, "idiopathic cytopenia(s) of undetermined significance" (ICUS) or "idiopathic dysplasia of undetermined significance" (IDUS), while awaiting clarifying information or further clinical developments. In the future, advances in molecular pathology will improve diagnostic accuracy, especially in morphologically non-descript cases.

journal_name

Curr Hematol Malig Rep

authors

Steensma DP

doi

10.1007/s11899-012-0140-3

subject

Has Abstract

pub_date

2012-12-01 00:00:00

pages

310-20

issue

4

eissn

1558-8211

issn

1558-822X

journal_volume

7

pub_type

杂志文章,评审
  • Artificial Intelligence in Hematology: Current Challenges and Opportunities.

    abstract:PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00575-4

    authors: Radakovich N,Nagy M,Nazha A

    更新日期:2020-06-01 00:00:00

  • Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?

    abstract::Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0371-4

    authors: Dhawan R,Marks DI

    更新日期:2017-04-01 00:00:00

  • Correction to: Strategies for Predicting Response to Checkpoint Inhibitors.

    abstract::The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...

    journal_title:Current hematologic malignancy reports

    pub_type: 已发布勘误

    doi:10.1007/s11899-018-0488-0

    authors: Zappasodi R,Wolchok JD,Merghoub T

    更新日期:2019-02-01 00:00:00

  • Antibody therapy for acute lymphoblastic leukemia.

    abstract::Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0120-7

    authors: Portell CA,Advani AS

    更新日期:2012-06-01 00:00:00

  • Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

    abstract::Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0369-y

    authors: Sethi TK,Basdag B,Bhatia N,Moslehi J,Reddy NM

    更新日期:2017-06-01 00:00:00

  • Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?

    abstract::Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-011-0099-5

    authors: Forstpointner R,Dreyling M

    更新日期:2011-12-01 00:00:00

  • Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.

    abstract::Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0293-y

    authors: Chung CG,Poligone B

    更新日期:2015-12-01 00:00:00

  • Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

    abstract:PURPOSE OF REVIEW:To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS:Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognosti...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-019-00514-y

    authors: Mina AA,Stein B

    更新日期:2019-06-01 00:00:00

  • Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?

    abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0129-y

    authors: Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

    更新日期:2012-09-01 00:00:00

  • New aspects of the treatment of chronic lymphocytic leukemia.

    abstract::Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-006-0006-7

    authors: Faderl S,Wierda W,Keating MJ

    更新日期:2006-12-01 00:00:00

  • What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?

    abstract:PURPOSE OF REVIEW:Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. RECENT FINDINGS:CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer h...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-019-00555-3

    authors: Gale RP,Apperley J

    更新日期:2019-12-01 00:00:00

  • Primary mediastinal large B-cell lymphoma.

    abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-014-0219-0

    authors: Dabrowska-Iwanicka A,Walewski JA

    更新日期:2014-09-01 00:00:00

  • The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.

    abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00596-z

    authors: Patel AA,Odenike O

    更新日期:2020-12-01 00:00:00

  • The Effect of Psychosocial Interventions on Outcomes for Caregivers of Hematopoietic Cell Transplant Patients.

    abstract:PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0445-y

    authors: Bangerter LR,Griffin JM,Langer S,Hasan B,Kim WS,Murad MH,Khera N

    更新日期:2018-06-01 00:00:00

  • The Critical Role of Imaging in the Management of Multiple Myeloma.

    abstract::Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0379-9

    authors: Raza S,Leng S,Lentzsch S

    更新日期:2017-06-01 00:00:00

  • Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

    abstract:PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0459-5

    authors: Chander U,Leeman-Neill RJ,Bhagat G

    更新日期:2018-08-01 00:00:00

  • Leveraging Hypomethylating Agents for Better MDS Therapy.

    abstract:PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0477-3

    authors: Bradley TJ,Watts JM,Swords RT

    更新日期:2018-12-01 00:00:00

  • Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

    abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0283-0

    authors: Karp Leaf R,Cho HJ,Avigan D

    更新日期:2015-12-01 00:00:00

  • Novel Immunotherapies for T Cell Lymphoma and Leukemia.

    abstract:PURPOSE OF REVIEW:Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0480-8

    authors: Ghione P,Moskowitz AJ,De Paola NEK,Horwitz SM,Ruella M

    更新日期:2018-12-01 00:00:00

  • Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.

    abstract::C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-013-0193-y

    authors: Callejas-Díaz A,Gea-Banacloche JC

    更新日期:2014-03-01 00:00:00

  • Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.

    abstract::The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0287-9

    authors: Pemmaraju N,Gupta V,Mesa R,Thompson MA

    更新日期:2015-12-01 00:00:00

  • Lenalidomide in myelodysplastic syndromes: where do we go from here?

    abstract::Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-008-0002-1

    authors: Sirulnik LA,Stone RM

    更新日期:2008-01-01 00:00:00

  • Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

    abstract::Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions w...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0405-y

    authors: Shaver AC,Seegmiller AC

    更新日期:2017-10-01 00:00:00

  • Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

    abstract:PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-019-00542-8

    authors: Torka P,Barth M,Ferdman R,Hernandez-Ilizaliturri FJ

    更新日期:2019-10-01 00:00:00

  • What Is the Optimal Induction Therapy for Younger Fit Patients With AML?

    abstract::Acute myeloid leukemia (AML) is a complex clonal disorder. The disease is characterized by chromosomal and molecular abnormalities that propagate and expand the abnormal clone(s). The main goal of therapy is to achieve and ultimately maintain a complete remission. In the younger AML patient (less than 60 years of age)...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-016-0339-9

    authors: Fernandez HF

    更新日期:2016-10-01 00:00:00

  • Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

    abstract::Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-014-0225-2

    authors: Selimoglu-Buet D,Solary E

    更新日期:2014-12-01 00:00:00

  • The GHSG Approach to Treating Hodgkin's Lymphoma.

    abstract::Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0262-5

    authors: Bröckelmann PJ,Engert A

    更新日期:2015-09-01 00:00:00

  • Recognizing unusual manifestations of Hodgkin lymphoma.

    abstract::Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0131-4

    authors: Barber NA,Bierman PJ

    更新日期:2012-09-01 00:00:00

  • Update on antigen-specific immunotherapy of acute myeloid leukemia.

    abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0250-9

    authors: Buckley SA,Walter RB

    更新日期:2015-06-01 00:00:00

  • Are MPNs vascular diseases?

    abstract::A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-013-0176-z

    authors: Finazzi G,De Stefano V,Barbui T

    更新日期:2013-12-01 00:00:00